ATE350396T1 - Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung - Google Patents

Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung

Info

Publication number
ATE350396T1
ATE350396T1 AT02726037T AT02726037T ATE350396T1 AT E350396 T1 ATE350396 T1 AT E350396T1 AT 02726037 T AT02726037 T AT 02726037T AT 02726037 T AT02726037 T AT 02726037T AT E350396 T1 ATE350396 T1 AT E350396T1
Authority
AT
Austria
Prior art keywords
peptides derived
medical use
neurofilament proteins
proteins
neurofilament
Prior art date
Application number
AT02726037T
Other languages
German (de)
English (en)
Inventor
Paul A Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Application granted granted Critical
Publication of ATE350396T1 publication Critical patent/ATE350396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
AT02726037T 2001-05-25 2002-05-24 Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung ATE350396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29315601P 2001-05-25 2001-05-25

Publications (1)

Publication Number Publication Date
ATE350396T1 true ATE350396T1 (de) 2007-01-15

Family

ID=23127882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726037T ATE350396T1 (de) 2001-05-25 2002-05-24 Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung

Country Status (17)

Country Link
US (1) US6924266B2 (enExample)
EP (1) EP1390403B1 (enExample)
JP (1) JP4584573B2 (enExample)
KR (1) KR100945383B1 (enExample)
CN (1) CN1582301A (enExample)
AT (1) ATE350396T1 (enExample)
AU (1) AU2002256587B2 (enExample)
BR (1) BR0209990A (enExample)
CA (1) CA2448348C (enExample)
CY (1) CY1111120T1 (enExample)
DE (1) DE60217326T2 (enExample)
DK (1) DK1390403T3 (enExample)
ES (1) ES2278916T3 (enExample)
NO (1) NO334189B1 (enExample)
NZ (1) NZ529911A (enExample)
PT (1) PT1390403E (enExample)
WO (1) WO2002097030A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207638A (pt) * 2001-03-08 2004-07-27 Nymox Pharmaceuticals Corp Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células
JP4587667B2 (ja) * 2001-07-19 2010-11-24 ナイモックス コーポレーション 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
EP1847550A3 (en) * 2001-07-19 2008-01-09 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2005075647A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
EP1732594A4 (en) * 2004-03-18 2007-10-17 St Lukes Hospital METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE
MX2008011570A (es) * 2006-03-10 2008-09-23 Nymox Corp Metodo para prevenir o reducir el riesgo o incidencia de cancer usando peptidos basados en proteina de hebra neural.
CN101215323B (zh) * 2007-12-28 2011-11-30 首都医科大学宣武医院 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
CN111579799A (zh) * 2020-06-23 2020-08-25 江苏省荣军医院 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE68927459T2 (de) 1988-12-21 1997-04-24 Gen Hospital Corp Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
KR20000075748A (ko) * 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
WO1999019347A1 (en) 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
JP2002519311A (ja) * 1998-06-26 2002-07-02 ジョージタウン・ユニバーシティ・メディカル・センター 細胞死を誘発するための組成物と方法
US7125957B1 (en) * 1998-09-30 2006-10-24 Riken VPR mutant protein and its encoding gene having apoptosis-inducing action
WO2000034477A2 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
ES2202039T3 (es) * 1999-01-11 2004-04-01 Leadd B.V. Uso de agentes inductores de apoptosis en la preparacion de mrdicamentto para el tratamiento de enfermedades autoinmunitarias.
JP2002541833A (ja) * 1999-03-26 2002-12-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
CA2368927A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 45 human secreted proteins
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
BR0207638A (pt) * 2001-03-08 2004-07-27 Nymox Pharmaceuticals Corp Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células
DE60205366T2 (de) * 2001-05-16 2006-05-24 Nymox Corp., Saint-Laurent Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine

Also Published As

Publication number Publication date
NO20035231D0 (no) 2003-11-25
JP2004534533A (ja) 2004-11-18
CY1111120T1 (el) 2015-06-11
NZ529911A (en) 2008-05-30
EP1390403B1 (en) 2007-01-03
KR20040038913A (ko) 2004-05-08
PT1390403E (pt) 2007-03-30
NO20035231L (no) 2004-01-26
DK1390403T3 (da) 2007-05-14
US20030096350A1 (en) 2003-05-22
AU2002256587B2 (en) 2008-04-03
KR100945383B1 (ko) 2010-03-05
BR0209990A (pt) 2004-06-29
WO2002097030A3 (en) 2003-10-30
EP1390403A2 (en) 2004-02-25
US6924266B2 (en) 2005-08-02
WO2002097030A2 (en) 2002-12-05
ES2278916T3 (es) 2007-08-16
DE60217326T2 (de) 2007-10-18
NO334189B1 (no) 2014-01-13
JP4584573B2 (ja) 2010-11-24
DE60217326D1 (de) 2007-02-15
CA2448348C (en) 2013-07-16
CN1582301A (zh) 2005-02-16
CA2448348A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
EA200400205A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
NZ333609A (en) Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
ATE443076T1 (de) Von protease typ ii spaltbares peptid
EA200001124A1 (ru) Способ генной терапии
DK1438329T3 (da) Biologisk aktive peptider og deres anvendelse til reparation af beskadigede nerver
EP1714979A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1847550A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390403

Country of ref document: EP